![]() |
||||
| A Pulsed Signal Therapy® foi desenvolvida por mais de 30 anos de pesquisas, e é uma tecnologia exclusiva e patenteada. | ||||
| 1970's | 1980's | 1990's | 2000's | |
| Completion of basic research on the constellation of energy
parameters of the PST® signal system. Basic animal research completed: 1971: New PST® device with 5th generation electronics. 1973: First PST® clinical study - in an orthopaedic doctors office. 1976: Completion of first clinical trials of PST®. In vitro studies in Germany. First process patent issued 5,131,904 (+52 subsequent patents) |
Development of a comprehensive PST® scientific plan. Discussions with leaders in the field of arthrosis. Discussions with physicists and engineers to develop the constellation of energy parameters required for the PST® signal. Initial discussion with universities to develop a clinical study and treatment protocol. Finalizing the clinical study program and initiation at Yale University School of medicine teaching hospitals. Presentation of PST® at university medical conferences. |
Developing a data base for PST® scientific abstracts. Clinical studies in Waterbury, Danbury; CT and Melville NY (under Yale university IRB approved protocol) Publication of various clinical studies in peer reviewed medical journals. Completion of a large number of in vitro studies (Cornell University; University of Siena, Charitee, Berlin) Presenting PST® at 60 scientific conferences and meetings. Completion of more than 25 clinical studies. Opening the first clinics in Germany in June 1996. Developing new applications for the PST® technology. Development of the full body device with a full body coil system and 273 degree effective angulation. |
2000: Clinical study completed in Singapore. 2002: Clinical study at Hôpital Cochin (France). Increasing geographical scale: Brazil (2002), Portugal (2002), Italy (2004) 2003: Launch of the PST® Mobile device 2004: Evolution of the full bed device equiped with a double-coil system 2005: Creation of Groupe President Medical 2007: GPM acquires PST® patented technology. Clinical study at Tor Vergata hospital (Italy).
|
|